Guselkumab demonstrated an independent treatment effect in reducing fatigue after adjustment for clinical response-results from two phase 3 clinical trials of 1120 patients with active psoriatic arthritis.

Proton RahmanPhilip J MeasePhilip S HelliwellAtul DeodharLaure GossecArthur KavanaughAlexa P KollmeierElizabeth C HsiaBei ZhouXiwu LinMay ShawiChetan S KaryekarChenglong Han

Published in: Arthritis research & therapy (2021)

Name of the registry: ClinicalTrials.gov Trial registrations: DISCOVER-1, NCT03162796; DISCOVER-2, NCT03158285 Date of registration: DISCOVER-1, May 22, 2017; DISCOVER-2, May 18, 2017 URLs of the trial registry record: DISCOVER-1, https://clinicaltrials.gov/ct2/show/NCT03162796?term=NCT03162796&draw=1&rank=1 DISCOVER-2, https://clinicaltrials.gov/ct2/show/NCT03158285?term=NCT03158285&draw=2&rank=1.

Keyphrases

clinical trial
phase iii
phase ii
study protocol
computed tomography
preterm infants
image quality
contrast enhanced
magnetic resonance imaging
dual energy
randomized controlled trial
gestational age
open label
physical activity
smoking cessation
replacement therapy
pet ct